Novo CEO Doustdar Stays Bullish, Prioritizes Heritage in Rebrand
Novo's new CEO signals continuity over upheaval as the company rebrands after losing GLP-1 ground to Eli Lilly.
Novo Nordisk CEO Mike Doustdar, brought in last year to revitalize the Danish drugmaker after it lost GLP-1 marketing ground to Eli Lilly, is taking a measured line on the company's corporate rebrand. He says he does not make changes for the sake of change, according to reports from Fierce Pharma and Fierce Biotech.
The two outlets published identical coverage, so their accounts fully agree. Doustdar frames the rebrand as an effort to honor Novo's heritage while planning for the future, and he describes himself as 'still a bull' on the company's prospects.
The comments suggest a leadership style rooted in continuity rather than disruption, even as Novo works to regain its competitive footing. Neither report offers specifics on pipeline plans or the timeline for the rebrand.
Sources · 2
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.